# Trade Mark Journal No.2026/015 10 April 2026

## WO0000001895066 (5,10,42)

Office of origin: United States of America

Date of International Registration:19 November 2025
Date of designation in the UK: 19 November 2025

International priority date claimed: 18 November 2025 (United States of America) (99503488)

Class 5
  Pharmaceutical preparations for the treatment of erythropoietic porphyria (EPP), X-linked protoporphyria (XLPP), genetic diseases and disorders, dermatological diseases and disorders, hematological diseases and disorders, liver diseases and disorders, and photosensitivity.
Class 10
  Medical tools being devices for diagnosing erythropoietic protoporphyria; medical tools being devices for treating and diagnosing sun exposure.
Class 42
  Research and development of pharmaceuticals and biologics for the treatment of immunologic disorders, hematologic disorders, anemia disorders, oncologic disorders and renal disorders; none of the foregoing offered in connection with treatment of diseases or disorders relating to spinal discs; scientific research and development in the field of sun exposure and related disease risk; research and development of pharmaceuticals, biologic preparations and medicines in the field of sun exposure and related disease risk; medical research and development in the field of sun exposure and related disease risk; conducting surveys and questionnaires being surveys to detect sun exposure and related disease risk.

Disc Medicine, Inc.

Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA